Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification Requests and Recordkeeping, 77645-77647 [2010-31195]
Download as PDF
Federal Register / Vol. 75, No. 238 / Monday, December 13, 2010 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Centers for Disease Control and
Prevention
Time and Date: 9 a.m.–6 p.m., March 4,
2011 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the initial review, discussion, and
evaluation of ‘‘Pregnancy Risk Assessment
Monitoring System (PRAMS), DP11–001
Panel F.’’
Contact Person for More Information:
Donald Blackman, PhD, Scientific Review
Officer, CDC, National Center for Chronic
Disease Prevention and Health Promotion,
Office of the Director, Extramural Research
Program Office, 4770 Buford Highway, NE.,
Mailstop K–92, Atlanta, GA 30341,
Telephone: (770) 488–3023, e-mail:
DBY7@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Pregnancy
Risk Assessment Monitoring System
(PRAMS), DP11–001 Panel E, Initial
Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 10 a.m.–5 p.m., March 8,
2011 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of ‘‘Pregnancy Risk Assessment
Monitoring System (PRAMS), DP11–001
Panel E.’’
Contact Person for More Information:
Donald Blackman, Ph.D., Scientific Review
Officer, CDC, National Center for Chronic
Disease Prevention and Health Promotion,
Office of the Director, Extramural Research
Program Office, 4770 Buford Highway, NE.,
Mailstop K–92, Atlanta, GA 30341,
Telephone: (770) 488–3023, e-mail:
DBY7@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: December 2, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–31147 Filed 12–10–10; 8:45 am]
Dated: December 2, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–31146 Filed 12–10–10; 8:45 am]
wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Pregnancy
Risk Assessment Monitoring System
(PRAMS), DP11–001 Panel F, Initial
Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
VerDate Mar<15>2010
15:42 Dec 10, 2010
Jkt 223001
Dated: December 2, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–31143 Filed 12–10–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0622]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Color Additive
Certification Requests and
Recordkeeping
AGENCY:
Food and Drug Administration,
HHS.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the information collection provisions of
FDA’s regulations governing batch
certification of color additives
manufactured for use in foods, drugs,
cosmetics or medical devices in the
United States.
DATES: Submit either electronic or
written comments on the collection of
information by February 11, 2011.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
SUMMARY:
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Pregnancy
Risk Assessment Monitoring System
(PRAMS), DP11–001 Panel D, Initial
Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Centers for Disease Control and
Prevention
Monitoring System (PRAMS), DP11–001
Panel D.’’
Contact Person for More Information:
Donald Blackman, Ph.D., Scientific Review
Officer, CDC, National Center for Chronic
Disease Prevention and Health Promotion,
Office of the Director, Extramural Research
Program Office, 4770 Buford Highway, NE.,
Mailstop K–92, Atlanta, GA 30341,
Telephone: (770) 488–3023, e-mail:
DBY7@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
77645
Time and Date: 11 a.m.–3 p.m., February
25, 2011 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the initial review, discussion, and
evaluation of ‘‘Pregnancy Risk Assessment
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
E:\FR\FM\13DEN1.SGM
13DEN1
77646
Federal Register / Vol. 75, No. 238 / Monday, December 13, 2010 / Notices
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes Agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal Agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1
SUPPLEMENTARY INFORMATION:
Color Additive Certification Requests
and Recordkeeping—21 CFR Part 80
(OMB Control Number 0910–0216)—
Extension
FDA has regulatory oversight for color
additives used in foods, drugs,
cosmetics, and medical devices. Section
721(a) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C.
379e(a)) provides that a color additive
shall be deemed to be unsafe unless it
meets the requirements of a listing
regulation, including any requirement
for batch certification, and is used in
accordance with the regulation. FDA
lists color additives that have been
shown to be safe for their intended uses
in title 21 of the Code of Federal
Regulations (CFR). FDA requires batch
certification for all color additives listed
in 21 CFR part 74 and for all color
additives provisionally listed in 21 CFR
part 82. Color additives listed in 21 CFR
part 73 are exempted from certification.
The requirements for color additive
certification are described in part 80 (21
CFR part 80). In the certification
procedure, a representative sample of a
new batch of color additive,
accompanied by a ‘‘request for
certification’’ that provides information
about the batch, must be submitted to
FDA’s Office of Cosmetics and Colors.
FDA personnel perform chemical and
other analyses of the representative
sample and, providing the sample
satisfies all certification requirements,
issue a certification lot number for the
batch. FDA charges a fee for certification
based on the batch weight and requires
manufacturers to keep records of the
batch pending and after certification.
Under § 80.21, a request for
certification must include: Name of
color additive, manufacturer’s batch
number and weight in pounds, name
and address of manufacturer, storage
conditions, statement of use(s),
certification fee, and signature of person
requesting certification. Under § 80.22, a
request for certification must include a
sample of the batch of color additive
that is the subject of the request. The
sample must be labeled to show: Name
of color additive, manufacturer’s batch
number and quantity, and name and
address of person requesting
certification. Under § 80.39, the person
to whom a certificate is issued must
keep complete records showing the
disposal of all of the color additive
covered by the certificate. Such records
are to be made available upon request to
any accredited representative of FDA
until at least 2 years after disposal of all
of the color additive.
The purpose for collecting this
information is to help FDA assure that
only safe color additives will be used in
foods, drugs, cosmetics, and medical
devices sold in the United States. The
required information is unique to the
batch of color additive that is the subject
of a request for certification. The
manufacturer’s batch number is used for
temporarily identifying a batch of color
additive until FDA issues a certification
lot number and for identifying a
certified batch during inspections. The
manufacturer’s batch number also aids
in tracing the disposal of a certified
batch or a batch that has been denied
certification for noncompliance with the
color additive regulations. The
manufacturer’s batch weight is used for
assessing the certification fee. The batch
weight also is used to account for the
disposal of a batch of certified or
certification-denied color additive. The
batch weight can be used in a recall to
determine whether all unused color
additive in the batch has been recalled.
The manufacturer’s name and address
and the name and address of the person
requesting certification are used to
contact the person responsible should a
question arise concerning compliance
with the color additive regulations.
Information on storage conditions
pending certification is used to evaluate
whether a batch of certified color
additive is inadvertently or
intentionally altered in a manner that
would make the sample submitted for
certification analysis unrepresentative
of the batch. FDA checks storage
information during inspections.
Information on intended uses for a batch
of color additive is used to assure that
a batch of certified color additive will be
used in accordance with the
requirements of its listing regulation.
The statement of the fee on a
certification request is used for
accounting purposes so that a person
requesting certification can be notified
promptly of any discrepancies.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN1
Number of
respondents
21 CFR Section
80.21 ....................................................................................
VerDate Mar<15>2010
15:42 Dec 10, 2010
Jkt 223001
PO 00000
Frm 00041
Annual
frequency per
response
32
Fmt 4703
Sfmt 4703
Total annual
responses
185
E:\FR\FM\13DEN1.SGM
5,920
13DEN1
Hours per
response
0.17
Total hours
1,006
77647
Federal Register / Vol. 75, No. 238 / Monday, December 13, 2010 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN1—Continued
Number of
respondents
21 CFR Section
Annual
frequency per
response
Total annual
responses
Hours per
response
Total hours
80.22 ....................................................................................
32
185
5,920
0.05
296
Total ..............................................................................
........................
........................
........................
........................
1,302
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
Number of
recordkeepers
Annual
frequency of
recordkeeping
80.39 ....................................................................................
32
185
5,920
0.25
1,480
Total ..............................................................................
........................
........................
........................
........................
1,480
21 CFR Section
wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1
1 There
Total annual
records
Hours per
record
Total hours
are no capital costs or operating and maintenance costs associated with this collection of information.
FDA bases its estimate on its review
of the certification requests received
over the past 3 fiscal years (FY). The
annual burden estimate for this
information collection is 2,782 hours.
The estimated reporting burden for this
information collection is 1,302 hours
and the estimated recordkeeping burden
for this information collection is 1,480
hours. From FY 2008 to FY 2010, FDA
processed an average of 5,932 responses
(requests for certification of batches of
color additives) per year. There were 32
different respondents, corresponding to
an average of approximately 185
responses from each respondent per
year. Using information from industry
personnel, FDA estimates that an
average of 0.22 hour per response is
required for reporting (preparing
certification requests and accompanying
samples) and an average of 0.25 hour
per response is required for
recordkeeping.
FDA’s Web-based color certification
information system allows certifiers to
request color certification online, follow
their submissions through the process,
and obtain information on account
status. The system sends back the
certification results electronically,
allowing certifiers to sell their certified
color before receiving hard copy
certificates. Any delays in the system
result only from shipment of color
additive samples to FDA’s Office of
Cosmetics and Colors for analysis. FDA
has estimated a reduction in the hour
burden for reporting from use of the
Web-based system.
Dated: December 8, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–31195 Filed 12–10–10; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
15:42 Dec 10, 2010
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0389]
Medical Device User Fee Program;
Meetings on Reauthorization; Request
for Notification of Patient and
Consumer Advocacy Group Intention
to Participate
AGENCY:
Food and Drug Administration,
HHS.
Notice; request for notification
of participation.
ACTION:
The Food and Drug
Administration (FDA) is issuing this
notice to request that patient and
consumer advocacy groups notify FDA
of their intent to participate in periodic
consultation meetings on
reauthorization of the Medical Device
User Fee Amendments of 2007
(MDUFA) (the Food and Drug
Administration Amendments Act of
2007). The statutory authority for
MDUFA expires September 30, 2012. At
that time, new legislation will be
required for FDA to continue collecting
user fees for the medical device
program. The Federal Food, Drug, and
Cosmetic Act (the FD&C Act) requires
that FDA consult with a range of
stakeholders in developing
recommendations for the next MDUFA
program. The FD&C Act also requires
that FDA hold continued discussions
with representatives of patient and
consumer advocacy groups at least
monthly during FDA’s negotiations with
the regulated industry. The purpose of
this request for notification is to ensure
continuity and progress in these
discussions by establishing consistent
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
patient and consumer advocacy group
representation.
DATES: Submit notification of intention
to participate by January 6, 2011. The
first patient and consumer advocacy
group meeting will be held on January
13, 2011, from 9 a.m. to 11 a.m.
Meetings will continue at least monthly
during reauthorization negotiations with
the regulated industry.
ADDRESSES: Submit notification of
intention to participate in monthly
patient and consumer advocacy group
meetings by e-mail to
MDUFAReauthorization@fda.hhs.gov.
The first meeting will be held at the
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 31, rm.
1503 B and C, Silver Spring, MD 20993–
0002.
FOR FURTHER INFORMATION CONTACT:
Cindy Garris, Food and Drug
Administration, Center for Devices and
Radiological Health 10903 New
Hampshire Ave., Bldg. 66, rm. 4610,
Silver Spring, MD 20993–0002, 301–
796–5861, FAX: 301–847–8149.
SUPPLEMENTARY INFORMATION:
I. Introduction
The authority for MDUFA (Pub. L.
110–85) expires September 30, 2012.
Without new legislation to reauthorize
the program, FDA will no longer be able
to collect user fees to fund the medical
device program. Section 738A(b)(1) (21
U.S.C. 379j–1(b)(1)) of the FD&C Act
requires that FDA consult with a range
of groups in developing
recommendations for the next MDUFA
program, including scientific and
academic experts, health care
professionals, and representatives from
patient and consumer advocacy groups.
FDA initiated this process of
consultation on September 14, 2010, by
E:\FR\FM\13DEN1.SGM
13DEN1
Agencies
[Federal Register Volume 75, Number 238 (Monday, December 13, 2010)]
[Notices]
[Pages 77645-77647]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-31195]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0622]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Color Additive Certification Requests and
Recordkeeping
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the information collection
provisions of FDA's regulations governing batch certification of color
additives manufactured for use in foods, drugs, cosmetics or medical
devices in the United States.
DATES: Submit either electronic or written comments on the collection
of information by February 11, 2011.
ADDRESSES: Submit electronic comments on the collection of information
to https://
[[Page 77646]]
www.regulations.gov. Submit written comments on the collection of
information to the Division of Dockets Management (HFA-305), Food and
Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
All comments should be identified with the docket number found in
brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-3793.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Color Additive Certification Requests and Recordkeeping--21 CFR Part 80
(OMB Control Number 0910-0216)--Extension
FDA has regulatory oversight for color additives used in foods,
drugs, cosmetics, and medical devices. Section 721(a) of the Federal
Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 379e(a))
provides that a color additive shall be deemed to be unsafe unless it
meets the requirements of a listing regulation, including any
requirement for batch certification, and is used in accordance with the
regulation. FDA lists color additives that have been shown to be safe
for their intended uses in title 21 of the Code of Federal Regulations
(CFR). FDA requires batch certification for all color additives listed
in 21 CFR part 74 and for all color additives provisionally listed in
21 CFR part 82. Color additives listed in 21 CFR part 73 are exempted
from certification.
The requirements for color additive certification are described in
part 80 (21 CFR part 80). In the certification procedure, a
representative sample of a new batch of color additive, accompanied by
a ``request for certification'' that provides information about the
batch, must be submitted to FDA's Office of Cosmetics and Colors. FDA
personnel perform chemical and other analyses of the representative
sample and, providing the sample satisfies all certification
requirements, issue a certification lot number for the batch. FDA
charges a fee for certification based on the batch weight and requires
manufacturers to keep records of the batch pending and after
certification.
Under Sec. 80.21, a request for certification must include: Name
of color additive, manufacturer's batch number and weight in pounds,
name and address of manufacturer, storage conditions, statement of
use(s), certification fee, and signature of person requesting
certification. Under Sec. 80.22, a request for certification must
include a sample of the batch of color additive that is the subject of
the request. The sample must be labeled to show: Name of color
additive, manufacturer's batch number and quantity, and name and
address of person requesting certification. Under Sec. 80.39, the
person to whom a certificate is issued must keep complete records
showing the disposal of all of the color additive covered by the
certificate. Such records are to be made available upon request to any
accredited representative of FDA until at least 2 years after disposal
of all of the color additive.
The purpose for collecting this information is to help FDA assure
that only safe color additives will be used in foods, drugs, cosmetics,
and medical devices sold in the United States. The required information
is unique to the batch of color additive that is the subject of a
request for certification. The manufacturer's batch number is used for
temporarily identifying a batch of color additive until FDA issues a
certification lot number and for identifying a certified batch during
inspections. The manufacturer's batch number also aids in tracing the
disposal of a certified batch or a batch that has been denied
certification for noncompliance with the color additive regulations.
The manufacturer's batch weight is used for assessing the certification
fee. The batch weight also is used to account for the disposal of a
batch of certified or certification-denied color additive. The batch
weight can be used in a recall to determine whether all unused color
additive in the batch has been recalled. The manufacturer's name and
address and the name and address of the person requesting certification
are used to contact the person responsible should a question arise
concerning compliance with the color additive regulations. Information
on storage conditions pending certification is used to evaluate whether
a batch of certified color additive is inadvertently or intentionally
altered in a manner that would make the sample submitted for
certification analysis unrepresentative of the batch. FDA checks
storage information during inspections. Information on intended uses
for a batch of color additive is used to assure that a batch of
certified color additive will be used in accordance with the
requirements of its listing regulation. The statement of the fee on a
certification request is used for accounting purposes so that a person
requesting certification can be notified promptly of any discrepancies.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
Annual
21 CFR Section Number of frequency per Total annual Hours per Total hours
respondents response responses response
----------------------------------------------------------------------------------------------------------------
80.21........................... 32 185 5,920 0.17 1,006
[[Page 77647]]
80.22........................... 32 185 5,920 0.05 296
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 1,302
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Table 2--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
Annual
21 CFR Section Number of frequency of Total annual Hours per Total hours
recordkeepers recordkeeping records record
----------------------------------------------------------------------------------------------------------------
80.39........................... 32 185 5,920 0.25 1,480
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 1,480
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
FDA bases its estimate on its review of the certification requests
received over the past 3 fiscal years (FY). The annual burden estimate
for this information collection is 2,782 hours. The estimated reporting
burden for this information collection is 1,302 hours and the estimated
recordkeeping burden for this information collection is 1,480 hours.
From FY 2008 to FY 2010, FDA processed an average of 5,932 responses
(requests for certification of batches of color additives) per year.
There were 32 different respondents, corresponding to an average of
approximately 185 responses from each respondent per year. Using
information from industry personnel, FDA estimates that an average of
0.22 hour per response is required for reporting (preparing
certification requests and accompanying samples) and an average of 0.25
hour per response is required for recordkeeping.
FDA's Web-based color certification information system allows
certifiers to request color certification online, follow their
submissions through the process, and obtain information on account
status. The system sends back the certification results electronically,
allowing certifiers to sell their certified color before receiving hard
copy certificates. Any delays in the system result only from shipment
of color additive samples to FDA's Office of Cosmetics and Colors for
analysis. FDA has estimated a reduction in the hour burden for
reporting from use of the Web-based system.
Dated: December 8, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-31195 Filed 12-10-10; 8:45 am]
BILLING CODE 4160-01-P